Participants were randomly assigned to receive subcutaneous romosozumab monthly ( at a dose of @ mg , @ mg , or @ mg ) or every @ months ( @ mg or @ mg ) , subcutaneous placebo , or an open-label active comparator -- oral alendronate ( @ mg weekly ) or subcutaneous teriparatide ( @ g daily ) .